Decoy Therapeutics Inc.
DCOY
$2.99
$0.010.34%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -147.84% | -30.13% | -513.27% | 10.14% | 32.76% |
| Total Depreciation and Amortization | 1,136.36% | 436.36% | 245.45% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 788.79% | 535.82% | 16,862.55% | -62.00% | -72.77% |
| Change in Net Operating Assets | -798.46% | -279.18% | -221.56% | -78.86% | -73.20% |
| Cash from Operations | -207.55% | -144.50% | -53.06% | -21.38% | 19.58% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 100.00% | 4.02% |
| Issuance of Common Stock | -- | -- | -- | 307.67% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,340.01% | -- | 5,774.77% | 328.50% | -400.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.69% | -354.22% | 794.56% | 35,746.43% | 8.81% |